Neurocrine Biosciences (NBIX) Short Interest Ratio & Short Volume

Short interest is the volume of Neurocrine Biosciences shares that have been sold short but have not yet been covered or closed out. As of May 15th, traders have sold 1,860,000 shares of NBIX short. Learn More on Neurocrine Biosciences' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NBIX shares currently have a short interest ratio of 2.0. Learn More on Neurocrine Biosciences's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Neurocrine Biosciences: Walleye Trading LLC, Jane Street Group LLC, Torno Capital LLC, PEAK6 Investments LLC, Concourse Financial Group Securities Inc., Simplex Trading LLC, Portman Square Capital LLP, and Curated Wealth Partners LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Neurocrine Biosciences saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,860,000 shares, an increase of 1.6% from the previous total of 1,830,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the sector of "medical" compare to Neurocrine Biosciences: Bio-Techne Co. (4.26%), Qiagen (1.39%), CRISPR Therapeutics AG (18.05%), Denali Therapeutics Inc. (8.09%), Adaptive Biotechnologies Co. (8.92%), Biogen Inc. (2.41%), Alnylam Pharmaceuticals, Inc. (2.01%), BioMarin Pharmaceutical Inc. (1.97%), Incyte Co. (3.36%), United Therapeutics Co. (9.14%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

Short selling NBIX is an investing strategy that aims to generate trading profit from Neurocrine Biosciences as its price is falling. NBIX shares are trading down $5.86 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Neurocrine Biosciences occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NBIX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NBIX, twice per month. The most recent reporting period available is May, 15 2024.